Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metas… Ended

2023-505009-17-00 Triple-negative Breast Cancer 5 2019-06-21
ABCSG 45: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin… Ended

2024-512821-10-00 Early invasive triple negative breast cancer with posit 4 2019-06-17
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selecte… Ended

2024-513915-28-00 Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, 3 2019-06-14
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended

2023-509848-10-00 Multiple myeloma (MM) with at least 2 prior therapies i 5 2019-06-12
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma… Ended

2024-511316-25-00 Urothelial carcinoma (UC) 3 2019-06-04
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended

2024-510984-52-00 Patients with tumors 1 2019-05-24
An phase I study of BI 765063 (a monoclonal antibody) as single agent and in combination with BI 754091 (a PD-1) to characterize safety, pha… Ended

2024-519150-37-00 Patients with advanced solid tumour 7 2019-05-21
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 5 2019-05-20
Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended

2024-513731-24-00 Non-small cell lung cancer (NSCLC) 4 2019-05-14
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients w… Ended

2024-511956-42-00 Metastatic Non-Small Cell Lung Cancer (NSCLC) 3 2019-05-14
A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumo… Ended

2024-519176-95-00 Gastrointestinal Stromal Tumors (GIST) 4 2019-05-08
Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum) Ended

2024-512855-19-00 Rectal adenocarcinoma 4 2019-04-30
Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended

2023-508832-68-00 Recurrent or stage IVB cervical cancer 9 2019-03-28
Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with ref… Ended

2024-513470-22-00 Progressive or refractory paediatric solid tumor 9 2019-03-22
MK-4280 and Pembrolizumab in Hematologic Malignancies Ended

2023-503587-17-00 Hematologic malignancies 9 2019-03-20
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. Ended

2023-507777-18-00 Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell 4 2019-03-19
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 5 2019-03-04
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on… Ended

2023-509800-14-00 extensive stage small cell lung cancer 3 2019-02-25
This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended

2022-502747-35-00 Newly diagnosed advanced (FIGO stage III-IV) high grade 5 2019-02-18